Citations

Clear

3138 citation(s) found for "Smith, AM".

Dementia occurring over a 32‐year follow‐up attributable to hypertension observed at different ages: Implications for dementia prevention
Smith, Jason R. , Sharrett, A. Richey , Pike, James Russell , Lee, Mark , Lutsey, Pamela L. , Palta, Priya, Windham, B. Gwen, Lutsey, Pamela L , Pike, James R , Smith, Jason R , Gottesman, Rebecca F. , Knopman, David S. , Coresh, Josef , Deal, Jennifer A.

Mayo Clinic

Alzheimer's & Dementia | February 18, 2023 | Volume: 19 | Issue: 8 | Pages: 3435-3447

10.1002/alz.12984 | PMID 36808817 Get It

AbstractINTRODUCTIONThe fraction of dementia attributable to hypertension might vary depending on the age of the population considered and the age through which dementia occurs.METHODSIn the Atherosclerosis Risk in Communities study, we quantified population attributable fractions (PAF) of dementia by age 80 and 90 from hypertension assessed at ages of 45–54 (n = 7572), 55–64 (n = 12,033), 65–74 (n = 6561), and 75–84 (n = 2086).RESULTSThe PAF for dementia by age 80 from all non‐normal blood pressure at ages 45–54 was 15.3% (95% confidence interval [CI] = 6.9%–22.3%), 19.1% (95% CI = 9.9%–26.9%) at ages 55–64, and 19.9% (95% CI = −4.4%–38.5%) at ages 65–74. The strongest PAFs were from stage 2 hypertension (11.9%–21.3%). For dementia by age 90, PAFs from non‐normal blood pressure up through age 75 were smaller (10.9%–13.8%), and non‐significant by age 75–84.DISCUSSIONInterventions targeting hypertension even in early late life might reduce a sizeable proportion of dementia.Highlights We estimated prospective population attributable risks of dementia for hypertension. 15%–20% of dementia cases by age 80 are from non‐normal blood pressure (BP). Associations between hypertension and dementia persisted through age 75. Midlife to early late‐life BP control might reduce a large proportion of dementia.
21. Efficacy of Commonly Utilized Resources in Preparation for the Plastic Surgery In-Service Examination
Spronsen, Nicole Van , Shrout, Maxwell, Rangel, India , Gill, Vikram, Harrington, M., Smith, Anthony A., Kandi, Lyndsay A. , Adeleye, Olufunmilola

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | February 16, 2023 | Volume: 11 | Issue: 2S | Pages: 13-14

10.1097/01.gox.0000921632.71209.6a Get It

Incidence of Glaucoma-Related Adverse Events in the First 5 Years After Pediatric Lensectomy
Bothun, Erick D. , Repka, Michael X. , Kraker, Raymond T. , Leske, David A. , Li, Zhuokai , Astle, William F., Holmes, Jonathan M. , Group, Pediatric Eye Disease Investigator, Wallace, David K. , Enyedi, Laura B. , Jones, Sarah K., Hug, Denise, Stahl, Erin D., Dent, Rebecca J., Kong, Lingkun , Wang, Serena , Gallerson, Bryan K., Hutchinson, Amy K., Lenhart, Phoebe D. , Brower, Judy, Morrison, David G., Ruark, Scott T., Mets-Halgrimson, Rebecca, Yoon, Hawke , Hamidullah, Aaliyah, Anderson, Jill S., Holleschau, Ann M., Superstein, Rosanne , Bélanger, Caroline, Fallaha, Nicole, Hamel, Patrick , Thibeault, Maryse, Tamkins, Susanna M. , Park, Hee-Jung S., Trumler, Anya A., Liu, Xiaonong, Sanders, Emi , McOwen, Diana C., Gray, Michael E. , Yang, Michael B. , Bowman, Corey S., Galvin, Jennifer, Therriault, Margaret, Smith, Heather , Whitaker, Michele E., Örge, Faruk , Grigorian, A. Paula, Baird, Alicia M., Strominger, Mitchell B. , Klein, Shelley, Kemmer, Jacquelyn D., Neiman, Alexandra E., Mendoza, Myra N., Frohwein, Jill J., Bremer, Don L., Cassady, Cybil, Golden, Richard P., Jordan, Catherine O., Oravec, Sara A., Yanovitch, Tammy L. , Lunsford, Keven, Nye, Christina, Shea, Caroline, Stillman, SueAnn M., Iderstine, Stephen C. Van, Robertson, Elisa, Cruz, Oscar A., Ghadban, Rafif, Govreau, Dawn, Longmuir, Susannah Q. , Shan, Xiaoyan, Taylor, Kate , Powell, Christine, Hammond, Benjamin P., Gearinger, Matthew D., Czubinski, Andrea, Salvin, Jonathan, Fisher, Alicia, Lee, Katherine A., Brooks, Daniel , Schweinler, Bonita R., Sala, Nicholas A., Sala, Allyson M., Summers, Allison I. , Karr, Daniel J. , Wilson, Lorri B., Rauch, Paula K., O’Hara, Mary, Gandhi, Nandini, Hashmi, Tania, Colburn, Jeffrey, Dittman, Eileen, Whitfill, Charles R., Wheeler, Amy M., McCourt, Emily A. , Singh, Jasleen , Welnick, Nanastasia, Azar, Nathalie F., Baker, Joseph, Droste, Patrick J. , Peters, Robert J., Hilbrands, Jan, Pineles, Stacy L., Bernardo, Marianne J., Peterson, Edward, Peterson, Charla H., Kumar, Kartik , Melese, Ephrem, Lingua, Robert W., Grijalva, Jeff, Crouch, Earl R., Crouch, Earl R., Ventura, Gaylord, Anninger, William, Benson, Shawn L., Karp, Karen A. , Smith, Jordana M., Brickman-Kelleher, Jill, Ticho, Benjamin H., Khammar, Alexander J., Clausius, Deborah A., Guo, Suquin, Chamberlain, Carolyn, Schloff, Susan, Madigan, William P., Burkman, Donna, Ramsey, Jean E., McConnell, Kate H. , Friedman, Ilana, Rosado, José , Sauberan, Donald P., Hemberger, Jody C., Davis, Patricia L., Rudaitis, Indre, Lowery, Robert S., Cupit, Shawn, Mohney, Brian G., Wernimont, Suzanne M., Neilsen, Rebecca A., Baran, Francine, Gladstone, Amy, Smith, Justin , Mellott, Mei, Kieser, Troy, Erzurum, S. Ayse , Colon, Beth, Shah, Birva, Quebbemann, Micaela, Austin, Darrell S., Boyle, Nicole M., Conner, Courtney L., Chandler, Danielle L. , Donahue, Quayleen, Fimbel, Brooke P., Robinson, Julianne L., Hercinovic, Amra, Hoepner, James E., Kaplon, Joseph D., Melia, Michele , Ortiz, Gillaine, Woodard, Victoria C., Stutz, Kathleen M., Sutherland, Desirae R. , Everett, Donald F., Diener‐West, Marie , Baker, John D., Davis, Barry R. , Phelps, Dale L. , Poff, Stephen W., Tychsen, Lawrence , Bradfield, Yasmin S., Foster, Nicole C. , Plager, David A. , Salchow, Daniel J. , Silver, Jayne L., Weise, Katherine K., Verderber, Lisa C. , Dean, Trevano W., Yen, Kimberly G., Campomanes, Alejandra G. de Alba , Young, Marielle P. , Rahmani, Bahram , Haider, Kathryn M. , Whitehead, George F., Lambert, Scott R. , Kurup, Sudhi P. , Kraus, Courtney L. , Wu, Rui, Hatt, Sarah R. , Freedman, Sharon F. , Cotter, Susan A. , Group, Pediatric Eye Disease Investigator, Prakalapakorn, Sasapin Grace , Ranaivo, Hantamalala Ralay , Areaux, Raymond G. , Chang, Ta Chen , Traboulsi, Elias I. , Ghasia, Fatema F. , Chen, Vicki, Rogers, David L. , LaRoche, G. Robert, Larson, Scott A. , Clarke, Michael W. , Hendricks, Dorothy H. , Jin, Jing , Brooks, Daniel, Rauch, Paula K., Baker, Joseph, Peterson, Edward, Crouch, Earl R., Suh, Donny Won , Christiansen, Stephen P. , Herlihy, Erin P. , Beck, Roy W. , Henderson, Robert J. , Saunders, Richard Anthony , Birch, Eileen E. , Manny, Ruth E. , Holmes, Jonathan M.

Mayo Clinic

JAMA Ophthalmology | February 16, 2023 | Volume: 141 | Issue: 4 | Pages: 324

10.1001/jamaophthalmol.2022.6413 | PMID 36795393 Get It

ImportanceGlaucoma can develop following cataract removal in children.ObjectiveTo assess the cumulative incidence of glaucoma-related adverse events (defined as glaucoma or glaucoma suspect) and factors associated with risk of these adverse events in the first 5 years after lensectomy prior to 13 years of age.Design, Setting, and ParticipantsThis cohort study used longitudinal registry data collected at enrollment and annually for 5 years from 45 institutional and 16 community sites. Participants were children aged 12 years or younger with at least 1 office visit after lensectomy from June 2012 to July 2015. Data were analyzed from February through December 2022.ExposuresUsual clinical care after lensectomy.Main Outcomes and MeasuresThe main outcomes were cumulative incidence of glaucoma-related adverse events and baseline factors associated with risk of these adverse events.ResultsThe study included 810 children (1049 eyes); 443 eyes of 321 children (55% female; mean [SD] age, 0.89 [1.97] years) were aphakic after lensectomy, and 606 eyes of 489 children (53% male; mean [SD] age, 5.65 [3.32] years) were pseudophakic. The 5-year cumulative incidence of glaucoma-related adverse events was 29% (95% CI, 25%-34%) in 443 eyes with aphakia and 7% (95% CI, 5%-9%) in 606 eyes with pseudophakia; 7% (95% CI, 5%-10%) of aphakic eyes and 3% (95% CI, 2%-5%) of pseudophakic eyes were diagnosed as glaucoma suspect. Among aphakic eyes, a higher risk for glaucoma-related adverse events was associated with 4 of 8 factors, including age less than 3 months (vs ≥3 months: adjusted hazard ratio [aHR], 2.88; 99% CI, 1.57-5.23), abnormal anterior segment (vs normal: aHR, 2.88; 99% CI, 1.56-5.30), intraoperative complications at time of lensectomy (vs none; aHR, 2.25; 99% CI, 1.04-4.87), and bilaterality (vs unilaterality: aHR, 1.88; 99% CI, 1.02-3.48). Neither of the 2 factors evaluated for pseudophakic eyes, laterality and anterior vitrectomy, were associated with risk of glaucoma-related adverse events.Conclusions and RelevanceIn this cohort study, glaucoma-related adverse events were common after cataract surgery in children; age less than 3 months at surgery was associated with elevated risk of the adverse events in aphakic eyes. Children with pseudophakia, who were older at surgery, less frequently developed a glaucoma-related adverse event within 5 years of lensectomy. The findings suggest that ongoing monitoring for the development of glaucoma is needed after lensectomy at any age.
Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection
Sims, Matthew , Khanna, Sahil , Louie, Thomas , Kelly, Colleen , Hohmann, Elizabeth , Wang, Elaine E. L., Oneto, Caterina , Cohen, Stuart H. , Berenson, Charles S., Korman, Louis Y. , Lee, Christine , Lashner, Bret A., Kraft, Colleen S., Ramesh, Mayur , Silverman, Michael H. , Pardi, Darrell S. , Hasson, Brooke , McGovern, Barbara , Moltke, Lisa Von, Investigators, ECOSPOR IV, Hemaidan, Anmar, Kumar, Princy , Misra, Bharat , Nathan, Richard, Pullman, John, Williams, Jeffrey G., Acosta, Idalia, Odio, Alberto, Smith, Kent, Hansen, Val, Georgetson, Michael, Sheikh, Aasim , Arimie, Calin, Andrade, Gladys, O’Marro, Steven, Esfandyari, Tuba, Ritter, Timothy E., Baird, Ian Mcnicol, Colman, Ronald, Hernandez, Lilliam, Adams, Atoya, Walton, Marie, Arsenescu, Razvan, Shapiro, Max, Cook, Paul, Heuer, Marvin, Bogdanovich, Tatiana, Grimard, Doria, Butt, Debra, Gauthier, Stephanie , Guímont, Chantal, Kreines, Michael, Berman, Larry, Bennett, Michael , Fogel, Ronald, Gutierrez, Juan Carlos Moises, Pedersen, P.C. , Bressler, Adam, Nadar, Venkatesh, Newton, Eric, Abbas, Jalal, Jamal, Aamir, Benjamin, Sabrina, Ayub, Kamran, Oguchi, Godson, Pinero, Jose, Ramesh, Gowrappala, Sepe, Paul S., Brook, Loren, Ruthardt, Frederick, Surace, Lindsey, Hussain, Ayub, Rutland, Travis J., Schmalz, Micahel, Degala, Gourisankar, Phillips, Raymond E. , Stock, Kent, Bullock, Jeffrey, Onwueme, Kenolisa, Feuerstadt, Paul , Huang, Edward S. , Lee, Christine H. , Kraft, Colleen S. , Silverman, Michael, De, Ananya, Memisoglu, Asli, Lombardi, David A., Investigators, ECOSPOR IV, Nguyen, Hien , Tran, Huy, Smith, Kent, Weinstock, Leonard B. , Garcia‐Diaz, Julia , Colman, Ronald, Patel, Meenakshi, Shapiro, Max, Cook, Paul, Steiner, Theodore S. , Butt, Debra, Daley, Peter , Gauthier, Stephanie, Berman, Larry, Bennett, Michael, Pedersen, Peder, Newton, Eric, Diaz, Jorge, Abbas, Jalal, DuPont, Herbert L. , Jamal, Aamir, Talreja, Neetu, Ayub, Kamran, Phillips, Raymond

Mayo Clinic

JAMA Network Open | February 13, 2023 | Volume: 6 | Issue: 2 | Pages: e2255758

10.1001/jamanetworkopen.2022.55758 | PMID 36780159 Get It

ImportanceA safe and effective treatment for recurrent Clostridioides difficile infection (CDI) is urgently needed. Antibiotics kill toxin-producing bacteria but do not repair the disrupted microbiome, which promotes spore germination and infection recurrence.ObjectivesTo evaluate the safety and rate of CDI recurrence after administration of investigational microbiome therapeutic SER-109 through 24 weeks.Design, Setting, and ParticipantsThis phase 3, single-arm, open-label trial (ECOSPOR IV) was conducted at 72 US and Canadian outpatient sites from October 2017 to April 2022. Adults aged 18 years or older with recurrent CDI were enrolled in 2 cohorts: (1) rollover patients from the ECOSPOR III trial who had CDI recurrence diagnosed by toxin enzyme immunoassay (EIA) and (2) patients with at least 1 CDI recurrence (diagnosed by polymerase chain reaction [PCR] or toxin EIA), inclusive of their acute infection at study entry.InterventionsSER-109 given orally as 4 capsules daily for 3 days following symptom resolution after antibiotic treatment for CDI.Main Outcomes and MeasuresThe main outcomes were safety, measured as the rate of treatment-emergent adverse events (TEAEs) in all patients receiving any amount of SER-109, and cumulative rates of recurrent CDI (toxin-positive diarrhea requiring treatment) through week 24 in the intent-to-treat population.ResultsOf 351 patients screened, 263 were enrolled (180 [68.4%] female; mean [SD] age, 64.0 [15.7] years); 29 were in cohort 1 and 234 in cohort 2. Seventy-seven patients (29.3%) were enrolled with their first CDI recurrence. Overall, 141 patients (53.6%) had TEAEs, which were mostly mild to moderate and gastrointestinal. There were 8 deaths (3.0%) and 33 patients (12.5%) with serious TEAEs; none were considered treatment related by the investigators. Overall, 23 patients (8.7%; 95% CI, 5.6%-12.8%) had recurrent CDI at week 8 (4 of 29 [13.8%; 95% CI, 3.9%-31.7%] in cohort 1 and 19 of 234 [8.1%; 95% CI, 5.0%-12.4%] in cohort 2), and recurrent CDI rates remained low through 24 weeks (36 patients [13.7%; 95% CI, 9.8%-18.4%]). At week 8, recurrent CDI rates in patients with a first recurrence were similarly low (5 of 77 [6.5%; 95% CI, 2.1%-14.5%]) as in patients with 2 or more recurrences (18 of 186 [9.7%; 95% CI, 5.8%-14.9%]). Analyses by select baseline characteristics showed consistently low recurrent CDI rates in patients younger than 65 years vs 65 years or older (5 of 126 [4.0%; 95% CI, 1.3%-9.0%] vs 18 of 137 [13.1%; 95% CI, 8.0%-20.0%]) and patients enrolled based on positive PCR results (3 of 69 [4.3%; 95% CI, 0.9%-12.2%]) vs those with positive toxin EIA results (20 of 192 [10.4%; 95% CI, 6.5%-15.6%]).Conclusions and RelevanceIn this trial, oral SER-109 was well tolerated in a patient population with recurrent CDI and prevalent comorbidities. The rate of recurrent CDI was low regardless of the number of prior recurrences, demographics, or diagnostic approach, supporting the beneficial impact of SER-109 for patients with CDI.Trial RegistrationClinicalTrials.gov identifier: NCT03183141
Pediatric Chemotherapy Infusions in Outpatient Examination Rooms: A Novel Patient Care Approach
Omdahl, Tami K., Stenzel, Janelle L., Pike, Marsha L., Conlon, Patricia M. , Barry, Tracy A., Brown, Tanya M. , Cambern, Kari L., Davis, Kadi M., Fjerstad, Kelly A., Graner, Kevin, Larson, Alison P., Soefje, Scott A. , Janssen, Alan M., Graner, Kevin K, Kuhn, Alexis K , Orandi, Amir B , Smith, Emily L., Soefje, Scott A , Omdahl, Tami K, Kuhn, Alexis , Orandi, Amir B. , Smith, Emily L.

Mayo Clinic

Journal of Pediatric Hematology/Oncology Nursing | February 13, 2023 | Volume: 40 | Issue: 3 | Pages: 195-202

10.1177/27527530221140067 | PMID 36775936 Get It

Background: Many health care organizations offer pediatric infusions in outpatient infusion centers or, as in our organization, in a hospital-based outpatient Pediatric Infusion Therapy Center (PITC). When restrictions related to the COVID-19 pandemic decreased our PITC appointment capacity by 40%, other patient and family satisfaction issues were exacerbated. We implemented a new approach to pediatric infusions with the aim of improving patient and family satisfaction and reducing the amount of time in an appointment itinerary without negatively affecting patient safety. Methods: Our team used a phased approach to pilot the administration of short chemotherapy infusions in the same outpatient clinic examination rooms where consultation and routine office visits were conducted. Patients saw their specialist for an examination and, if clinically indicated, their infusion was administered in the same room. Appointment itineraries were then completed. The team tracked efficiency, satisfaction, and safety metrics related to the new process. Results: All efficiency metrics improved. No harm came to the 49 unique patients who received a total of 184 infusions. Patient appointment itineraries were shortened by an average of 1.03 hr. Satisfaction survey responses indicated a clear preference (93%) for the new process. Discussion: The novel approach of offering short infusions in outpatient clinic examination rooms provides an opportunity to ease capacity constraints and further increase patient and family satisfaction. This method may be especially helpful for health care organizations when external influences (e.g., lack of physical space, challenging patient volumes, and pandemics) necessitate a change.
Design and quality control of large-scale two-sample Mendelian randomization studies
Haycock, Philip , Borges, Maria Carolina , Burrows, Kimberley , Harrison, Sean , Burgess, Stephen , Chang, Xuling , Khankari, Nikhil K. , Tsilidis, Kostas K, Gaunt, Tom R. , Hemani, Gibran , Zheng, Jie , Truong, Thérèse , Law, Matthew H. , Mariosa, Daniela , Hung, Rayjean J, Smith, George Davey , Relton, Caroline L. , Martin, Richard M. , Peters, Ulrike , Rice, Terri, Gallinger, Steve, Cornish, Alex J. , Vijayakrishnan, Jayaram , Wrensch, Margaret , Korat, Andres V Ardisson , Wheeler, Bill, Nilsson, Björn , Smith, Caren E. , Riadi, David, Claus, Elizabeth B. , Hosnijeh, Ng, Irene Oi‐Lin , Passow, Jeanette E, Han, Jiali , Schildkraut, Joellen M. , Wiemels, Joseph L. , Yang, Keming , Wu, Lang , Boutron, Marie-Christine, Iles, Mark M. , Stanulla, Martin , Gaudet, Mia M., Lenha, Mobuchon, Camp, Nicki J, Sham, Pak C. , Brennan, Paul , Jenkins, Robert B. , Diskin, Sharon J. , Berndt, Sonja I. , Tsavachidis, Spiridon, Channock, Stephen J., Galesloot, Tessel E. , Haycock, Philip , Harrison, Sean , Chang, Xuling , Zheng, Jie , Law, Matthew H , Birmann, Brenda M , Mariosa, Daniela , Zheng, Wei , Davey Smith, George , Borges, Maria C , Martin, Richard M , Iles, Mark M , Truong, Therese , Lemaître, Rozenn N. , Westra, Jason , Tsilidis, Kostas K, O’Mara, Tracy A. , Spurdle, Amanda B. , Slager, Susan L. , Birmann, Brenda M. , Hosnijeh, Fatemeh Saberi , Amos, Christopher I. , Hung, Rayjean J, Zheng, Wei , Gunter, Marc J. , Tintle, Nathan , Cheng, Iona C. , Jenkins, Mark A. , Sud, Amit , Johansson, Mattias , Norman, Aaron D. , Klein, Alison P. , Clay‐Gilmour, Alyssa , Franke, André , Heng, Chew‐Kiat , Song, Ci , Ellinghaus, Eva , Ostroumova, Evgenia , Vathaire, Florent de , Cugliari, Giovanni , Matullo, Giuseppe , Cerhan, James R. , Passow, Jeanette E. Eckel, Foo, Jia Nee , Liu, Jianjun , Barnholtz‐Sloan, Jill S. , Maris, John M. , Hemminki, Kari , Kiemeney, Lambertus A. , Ámundadóttir, Laufey T. , Stern, Marc‐Henri , Purdue, Mark P. , Bondy, Melissa L. , Guénel, Pascal , Taylor, Philip R. , Gharahkhani, Puya , Ostrom, Quinn T. , Stolzenberg‐Solomon, Rachael Z. , Dorajoo, Rajkumar , Houlston, Richard S. , Enroth, Stefan , Harrison, Tabitha A. , Gyllensten, Ulf B , Vijai, Joseph , Shi, Yufang , Yang, Wenjian , Lin, Yi , Van Den Eeden, Stephen K

Mayo Clinic

International Journal of Epidemiology | February 11, 2023 | Volume: 52 | Issue: 5 | Pages: 1498-1521

10.1093/ije/dyad018 | PMID 38587501 Get It

Abstract Background Mendelian randomization (MR) studies are susceptible to metadata errors (e.g. incorrect specification of the effect allele column) and other analytical issues that can introduce substantial bias into analyses. We developed a quality control (QC) pipeline for the Fatty Acids in Cancer Mendelian Randomization Collaboration (FAMRC) that can be used to identify and correct for such errors. Methods We collated summary association statistics from fatty acid and cancer genome-wide association studies (GWAS) and subjected the collated data to a comprehensive QC pipeline. We identified metadata errors through comparison of study-specific statistics to external reference data sets (the National Human Genome Research Institute-European Bioinformatics Institute GWAS catalogue and 1000 genome super populations) and other analytical issues through comparison of reported to expected genetic effect sizes. Comparisons were based on three sets of genetic variants: (i) GWAS hits for fatty acids, (ii) GWAS hits for cancer and (iii) a 1000 genomes reference set. Results We collated summary data from 6 fatty acid and 54 cancer GWAS. Metadata errors and analytical issues with the potential to introduce substantial bias were identified in seven studies (11.6%). After resolving metadata errors and analytical issues, we created a data set of 219 842 genetic associations with 90 cancer types, generated in analyses of 566 665 cancer cases and 1 622 374 controls. Conclusions In this large MR collaboration, 11.6% of included studies were affected by a substantial metadata error or analytical issue. By increasing the integrity of collated summary data prior to their analysis, our protocol can be used to increase the reliability of downstream MR analyses. Our pipeline is available to other researchers via the CheckSumStats package (https://github.com/MRCIEU/CheckSumStats).
A Delphi Method for Development of a Barrett’s Esophagus Question Prompt List as a Communication Tool for Optimal Patient-physician Communication
Kamal, A. N. , Wang, Chih-Hung Jason, Diehl, David L. , DuCoin, Christopher , Dunst, Christy M. , Iyer, Prasad G. , Katzka, David A. , Konda, Vani J. , Muthusamy, Raman, Otaki, Fouad , Rubenstein, Joel H. , Shaheen, Nicholas J. , Smith, Michael S. , Sujka, Joseph , Tatum, Roger P. , Ujiki, Michael , Wani, Sachin , Clarke, John O. , Clarke, J , Otaki, Fouad , Kamal, Afrin N., Triadafilopoulos, George , Falk, Gary W. , Muthusamy, Raman, Pleskow, Douglas K. , Sharma, Prateek , Swanström, Lee L. , Trindade, Arvind J.

Mayo Clinic

Journal of Clinical Gastroenterology | February 8, 2023 | Volume: 58 | Issue: 2 | Pages: 131-135

10.1097/mcg.0000000000001832 | PMID 36753462 Get It

Background Methods: The question prompt list content was derived through a modified Delphi process consisting of 3 rounds. In round 1, experts provided 5 answers to the prompts “What general questions should patients ask when given a new diagnosis of Barrett’s esophagus” and “What questions do I not hear patients asking, but given my expertise, I believe they should be asking?” Questions were reviewed and categorized into themes. In round 2, experts rated questions on a 5-point Likert scale. In round 3, experts rerated questions modified or reduced after the previous rounds. Only questions rated as “essential” or “important” were included in Barrett’s esophagus question prompt list (BE-QPL). To improve usability, questions were reduced to minimize redundancy and simplified to use language at an eighth-grade level (Fig. 1). Results: Twenty-one esophageal medical and surgical experts participated in both rounds (91% males; median age 52 years). The expert panel comprised of 33% esophagologists, 24% foregut surgeons, and 24% advanced endoscopists, with a median of 15 years in clinical practice. Most (81%), worked in an academic tertiary referral hospital. In this 3-round Delphi technique, 220 questions were proposed in round 1, 122 (55.5%) were accepted into the BE-QPL and reduced down to 76 questions (round 2), and 67 questions (round 3). These 67 questions reached a Flesch Reading Ease of 68.8, interpreted as easily understood by 13 to 15 years olds. Conclusions: With multidisciplinary input, we have developed a physician-derived BE-QPL to optimize patient-physician communication. Future directions will seek patient feedback to distill the questions further to a smaller number and then assess their usability.
ABCB7 deficiency causes ferroptosis in peripheral T cells
Lehrke, Michael Jonathan , Belmonte, Paul , Kennedy, Madeleine, Rajcula, Matthew, Shapiro, Virginia Smith

Mayo Clinic

The Journal of Immunology | February 7, 2023 | Volume: 206 | Issue: 1_Supplement | Pages: 98.42-98.42

10.4049/jimmunol.206.supp.98.42 Get It

Abstract ABCB7 exports iron-sulfur (Fe-S) clusters from the mitochondria into the cytoplasm. Conditional deletion of ABCB7 revealed that it is required for peripheral T cell homeostasis. CD4-cre ABCB7 cKO mice have normal thymic development, but a severe reduction in peripheral T cell numbers. A majority of the peripheral T cells in the ABCB7 cKO mice were recent thymic emigrants (RTEs), indicating a loss of more mature T cells in the periphery. T cell maturation markers were found to be normal and stimulation of ABCB7 cKO RTEs revealed normal levels of TNFα production. These data indicate that the loss of peripheral T cells in CD4-cre ABCB7 cKO mice was not due to a defect in development or maturation but a defect in peripheral homeostasis. ABCB7-deficient T cells did not have evidence of elevated apoptosis. We demonstrated iron accumulation was occurring in ABCB7-deficient peripheral T cells using the metal-specific dye Phen Green SK. Additionally, lipid peroxides levels were elevated in the ABCB7 cKO T cells. Lipid peroxides are a hallmark of ferroptosis, an iron-dependent form of regulated cell death. Expression of GPX4, the master regulator of ferroptosis, was normal in ABCB7 cKO T cells. In addition, levels of glutathione, which counteracts lipid peroxides were found to be normal, indicating the ferroptosis protection pathway was intact and that the iron overload was causing ferroptosis. Interestingly, treatment with the iron chelator deferoxamine did not rescue peripheral T cells in the CD4-cre ABCB7 cKO mice. Vitamin E, a potent antioxidant, also failed to rescue peripheral T cell homeostasis. Thus, ABCB7 is required to maintain iron homeostasis and its loss leads to peripheral T cell ferroptosis.
ST8Sia6 Overexpression Accelerates Tumorigenesis in a Siglec-E Dependent Manner Through Reshaping the Tumor Immune Microenvironment
Crotts, Sydney B. , Shapiro, M., Rajcula, Matthew, McCue, Shaylene , Khazaie, Khashayarsha , Friedman, David J. , Shapiro, Michael J, Dong, Haidong , Shapiro, Virginia Smith

Mayo Clinic

The Journal of Immunology | February 7, 2023 | Volume: 206 | Issue: 1_Supplement | Pages: 56.14-56.14

10.4049/jimmunol.206.supp.56.14 Get It

Abstract Checkpoint blockade has improved patient outcome through reinvigorating T cells against cancer. Despite this success, many patients don’t respond, leaving them with few options. Tumors utilize many immunosuppressive mechanisms, including altering the function of innate immune cells. Cancer cells can promote differentiation of macrophages into tolerogenic “M2-like” macrophages, which support tumor growth. Macrophage differentiation by cancer cells is influenced by many receptors, including Siglec-E. Siglec-E binds to α2,8-linked disialic acids, generated by the enzyme ST8Sia6, on O-linked glycoproteins, and functions to inhibit activation of innate immune cells. In some tumor types, higher expression of ST8Sia6 correlates with poorer survival. Therefore, ST8Sia6 overexpressing tumors may engage Siglec-E, leading to immune suppression and accelerating tumor growth. Mice injected with ST8Sia6 overexpressing MC38 and B16-F10 tumors had increased tumor burden, reduced survival and increased M2 macrophage polarization, which suppresses the immune response. This acceleration of tumor growth was abrogated when injected into Siglec-E knockout mice. Thus, the primary function of ST8Sia6 in tumors is an extrinsic alteration of the immune response, rather than an intrinsic effect on cell growth. Similarly, in a spontaneous colon cancer model, ST8Sia6 overexpression in a murine colon cancer model accelerated the development of tumors, decreasing survival to 2.5 months instead of 6 months. The overexpression of ST8Sia6 leads to increased Arg-1 expression by colonic tumor macrophages. Therefore, ST8Sia6 expression in tumors inhibits the immune response to promote tumor growth in a Siglec-E dependent manner.
Regulation of Inflammatory Bowel Disorder Inflammation by ST8Sia6
Crotts, Sydney B. , Shapiro, M., Rajcula, Matthew, Friedman, David J. , Shapiro, Michael J, Shapiro, Virginia Smith

Mayo Clinic

The Journal of Immunology | February 7, 2023 | Volume: 206 | Issue: 1_Supplement | Pages: 60.15-60.15

10.4049/jimmunol.206.supp.60.15 Get It

Abstract Inflammatory bowel disorders (IBD), including Crohn’s disease and colitis, have a prevalence between 10–20%. IBD patients experience a reduced quality of life due to symptoms such as diarrhea, abdominal cramps, anal bleeding. The exact etiology of IBD is incompletely understood, but the immune response plays a critical role. Innate immune cells integrate the sum of stimulatory and inhibitory signals to determine overall activation. Solidifying the roles of pertinent proteins and their interactions is critical in mapping the immune response and understanding the implications of clinical treatment of IBD. ST8Sia6 is a sialic acid transferase which adds terminal a2,8 disialic acids to cell surface glycoproteins, and we have found that ST8Sia6 generates ligands for Siglec-2 and Siglec-E on innate immune cells, including colonic macrophages and neutrophils. These siglecs are inhibitory sialic acid-binding membrane receptors expressed on several immune cell subsets. Restraining ST8Sia6 should therefore enhance the immune response by reducing siglec-mediated inhibition. To examine this, our lab has generated a novel ST8Sia6 knockout (KO) mouse. At baseline these mice are healthy, but we have found that ST8Sia6 KO mice challenged with dextran sodium sulfate (DSS)-induced colitis lose weight and succumb to colonic inflammation significantly faster than their wildtype (WT) counterparts, particularly at low doses. ST8Sia6 KO mice exhibit increased histological damage and immune infiltration of the colon and small bowel as compared to WT controls. This data demonstrates a role for ST8Sia6 in regulating the hose immune response to inflammatory bowel disorders.